Pharma Mirror Magazine

Emmes Acquires Clinical Edge, Company’s Fifth Acquisition Deepens Ophthalmology Credentials and Enhances Global Reach

October 1, 2022

ROCKVILLE, Md., Sept. 28, 2022 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and

Pharmaceutical News

Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc

October 1, 2022

Nanjing (China) and Barcelona (Spain), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical

Pharmaceutical News

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

September 16, 2022

REHOVOT, Israel & WILMINGTON Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule

Pharmaceutical News

Syntegon Group appoints Dr. Peter Hackel as Chief Financial Officer

September 16, 2022

Waiblingen/Germany, The Syntegon Group, a globally leadingsupplier of processing and packaging technology, intends to appoint Dr. Peter Hackelas member of

Pharmaceutical News

Almirall:Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis

September 16, 2022

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE,

Pharmaceutical News

Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines

September 11, 2022

Bandung, W Java, Indonesia, PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone

MORE NEWS

Emmes Acquires Clinical Edge, Company’s Fifth Acquisition Deepens Ophthalmology Credentials and Enhances Global Reach

Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Syntegon Group appoints Dr. Peter Hackel as Chief Financial Officer

Almirall:Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis

Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines